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[57] ABSTRACT 
Certain novel heterocyclic compounds, their prepara-
tion, and their use in inhibiting serine proteases with 
chymotrypsin-like, elastase-like, and trypsin-like speci-
ficity and in the treatment of diseases such as emphy-
sema which involve tissue proteolysis. 
2 Claims, No Drawings 
1 
4,596,822 
HETEROCYCLIC INHIBITORS OF SERINE 
PROTEASES 
2 
DETAILED DESCRIPTION OF THE 
INVENTION 
Certain substituted isocoumarins have been found to 
BACKGROUND OF THE INVENTION 5 be excellent inhibitors of a number of serine proteases 
including human leukocyte elastase, porcine pancreatic 
elastase, bovine chymotrypsin, human cathepsin G, 
various human and bovine blood coagulation enzymes, 
This invention relates to a novel class of heterocyclic 
compounds useful for selectively inhibiting elastase, 
selectively inhibiting chymotrypsin-like enzymes, selec-
tively inhibiting trypsin-like enzymes, or for generally 10 
inhibiting serine proteases of all classes. Certain clinical 
symptoms found in pancreatitis, emphysema, rheuma-
toid arthritis, inflammation, and adult respiratory dis-
tress syndrome are believed to be caused by uncon-
trolled elastase in the affected tissues. Likewise, similar 15 
clinical symptoms found in the same diseases are be-
lieved to be caused by uncontrolled cathepsin G, mast 
cell chymase, and other chymotrypsin-like enzymes. In 
vitro, proteolysis by serine proteases of the elastase, 
chymotrypsin, and trypsin families is often a severe 20 
problem in the production, isolation, purification, trans-
port and storage of valuable peptides and proteins. 
It is an object of this invention to find a novel group 
of specific inhibitors for elastase, chymotrypsin, trypsin, 
and other serine proteases of similar substrate specific- 25 
ity, and serine proteases in general. Inhibitors are sub-
stances which reduce or eliminate the catalytic activity 
human complement factor D, and several mammalian 
mast cell proteases. These compounds inhibit the serine 
proteases by acylating the active site serine residue and 
in some cases form an additional covalent bond. These 
structures may be used in vivo to treat diseases resulting 
from tissue destruction due to elastase, chymotrypsin, 
trypsin, and related enzymes. They may be used in vitro 
to prevent proteolysis that occurs during the produc-
tion, isolation, purification, storage, and transport of 
peptides and proteins. The novel substituted isocouma-
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y 
X is selected from the group consisting of 0 and S, 
Z is selected from the group consisting of H, halogen, 
Ct-6 alkyl, Ct-6 alkyl with an attached phenyl, Ct-6 fluo-
rinated alkyl, Ct-6 alkoxy, Ct-6 fluorinated alkoxy, Ct-6 
alkoxy with an attached phenyl, benzyloxy, 4-
fluorobenzyloxy, -OCH2C6Hs-R' (2-substituent), 
-OCH2C6Hs-R' (3-substituent), -OCH2C6Hs-R' (4-sub-
stituent), -OCH2C6"4-R2' (2,3-substituents), 
-OCH2C6"4R2' (2,4-substituents), -OCH2C6"4R2' (2,5-
substituents), -OCH2C6H4-R2' (2,6-substituents), 
-OCH2C6"4-R2' (3,4-substituents), and -OCH2C6H4-
R2' (3,5-substituents), 
R' is selected from the group consisting of H, halo-
gen, trifluoromethyl, N02, cyano, methyl, methoxy, 
acetyl, carboxyl, OH, and amino, 
Y is selected from the group consisting of H, halogen, 
trifluoromethyl, methyl, OH, and methoxy, 
of enzymes. Chymotrypsin and chymotrypsin-like en-
zymes normally cleave peptide bonds in proteins and 
peptides where the amino acid residue on the carbonyl 30 
side of the split bond (P1 residue) is typically Trp, Tyr, 
Phe, Met, Leu or other amino acid residues which con-
tain aromatic or large alkyl side chains. Elastase and 
elastase-like enzymes, on the other hand, cleave peptide 
bonds where the P1 amino acid residue is much smaller, 35 
typically Ala, Val, Ser, Leu and other similar amino 
acids. Trypsin-like enzymes hydrolyze peptide bonds 
where the P1 amino acid is Lys or Arg. All of the above 
enzymes have extensive secondary specificity and re~-
40 ognize amino acid residues removed from the P1 resi-
due. The inhibitors of this invention would be useful for 
treating diseases such as pancreatitis, emphysema, rheu-
matoid arthritis, adult respiratory distress syndrome, 
and inflammatory diseases which involve d~struction of 45 
tissue by serine proteases. In some cases, 1t would be 
more useful to utilize a specific elastase, trypsin or 
chymotrypsin-like enzyme inhibitor, while in other 
cases an inhibitor with broader specificity would be 
appropriate. 
R is selected from the group consisting of H, OH, 
NH2, N02, halogen, -NH-C(NH)-NH2, -C(NH)N2, 
50 Ct-6 alkoxy, Ct-6 fluorinated alkoxy, Ct-6 alkyl, Ct-6 
alkylamino, M-AA, and M-NH, It is an object of this invention to find a novel group 
of specific inhibitors useful in vitro for inhibiting elas-
tase, trypsin, chymotrypsin and other serine proteases 
of similar specificity, and for inhibiting serine proteases 
in general. Such inhibitors could be used to identify new 55 
proteolytic enzymes encountered in research. They 
could also be used in research and industrially to pre-
vent undesired proteolysis that occurs during the pro-
duction, isolation, purification, transport and storage of 
valuable peptides and proteins. Such proteolysis often 60 
destroys or alters the activity and/or function of the 
peptides and proteins. Uses would include the addition 
of the inhibitors to antibodies, enzymes, plasma prote-
ins, tissue extracts, or other proteins which are widely 
sold for use in clinical analysis, biomedical research, and 65 
for many other reasons. For some uses a specific inhibi-
tor would be desirable, while in other cases, an inhibitor 
with general specificity would be preferred. 
wherein AA is selected from the group consisting of 
alanine, valine, leucine, isoleucine, proline, methionine, 
phenylalanine, tryptophan, glycine, serine, threonine, 
cysteine, tyrosine, asparagine, glutamine, aspartic acid, 
glutamic acid, lysine, arginine, histidine, beta-alanine, 
norleucine, norvaline, alpha-aminobutyric acid, epsilon-
aminocaproic acid, citrulline, hydroxyproline, orni-
thine, and sarcosine, 
wherein M is selected from the group consisting of 
hydrogen, lower alkanoyl having 1 to 6 carbons, car-
boxylalkanoyl, hydroxyalkanoyl, amino-alkanoyl, ben-
zene sulfonyl, tosyl, benzoyl, and lower alkyl sulfonyl 
having 1 to 6 carbons. 
Several of these compounds have been prepared ear-
lier for other purposes (illustrative examples: Davies 
and Poole, J. Chem. Soc., pp 1616-1629, (1928); Milev-
skaya, Belinskaya, and Yagupol'skii, Zhur. Org. Khim. 
3 
4,596,822 
9, pp 2145-2149, (1973); Tirodkar and Usgaonkar, Ind. 
J. Chem. 7, pp 1114-1116, (1969); Choksey and Usgaon-
kar, Ind. J. Chem. 14B, pp 596-598, (1976)). 






Inactivation of Proteases by 3.4-Dichloroisocoumarin°. 
Enzyme 
Porcine Pancreatic Kallikrienc 
Bovine Factor Xac 























lO Human Factor Xllac 




































0 Inactivation measurements were performed using the incubation method in 0.1 M 
Hepes, 0.5 M NaCl, 8-10% Me2SO, pH 7.5 using the incubation method. An aliquot 
of inhibitor was added to an enzyme solution and aliquots removed with time and 
assayed for remaining enzymatic activity. First order rate constants, kobsd• were 
obtained from the slope of plots of In {v/v0 ) versus times. 
20 "Data obtained by progress curve method of Tian and Tsou, Biochemistry 21, 
1028-1032, (1982). 
yisocoumarin. 
When R is H, NH2, N02, X is 0, and Y and Z are any 25 
of the noted groups, the isocoumarin structure is a gen-
eral inhibitor for both human leukocyte (HL) elastase 
and bovine chymotrypsin. Although these substituted 
isocoumarins are slightly less effective toward porcine 
pancreatic (PP) elastase and cathepsin G, they are still 30 
capable of inhibiting these enzymes. The rate constants 
for inactivation of HL elastase, PP elastase, and chymo-
trypsin by 3-chloroisocoumarin (X=O, Z=CI, and 
Y =H) have been measured and are published, (Harper, 
Hemmi, and Powers, J. Amer. Chem. Soc. 105 , pp 35 
6518-6520 (1983)). 3-chloroisocoumarin also _inac-
tivates rat mast cell proteases I and II and Streptomyces 
griseus protease A with rates of 84, 85, and 196 M-1 
s-1, respectively. Rate constants for inactivation of a 
number of elastase, chymotrypsin, and trypsin-like en- 40 
zymes by 3,4-dichloroisocoumarin (R=H, X=O, 
Y =Z=CI) are given in Table I. This table indicates the 
generality of this compound as a serine protease inhibi-
tor. 
<incubation and assay bufTerwas0.1MHepes,5 mM CaCl2, 8-10% Me2SO, pH 7.5. 
dData obtained using the progress curve method (0.1 M Hepes, 5 mM CaCI2. 10% 
Me2SO, pH 7.5). 
'Buffer was 0.1 M Hepes, 10% MeiSO, pH 7.5. 
!Bulfer was 0.1 M phosphate, 10% Me2SO, pH 7.0. 
8NI, no inactivation. 
heuffer was 0.05 M Tris HCI, 5 mM cysteine, 2 mM ethylenediaminetetraacetic acid, 
10% Me2SO, pH 8.2. 
Table II shows the inactivation rate constants for 
several serine proteases inhibited by substituted 3-alkox-
yisocoumarins. These kabsdl[l] values are second order 
inactivation rate constants and reflect irreversible inac-
tivation of the enzyme. In some cases (see Tables I and 
II), inactivation rate constants were measured in the 
presence of substrate using the progress curve method 
as described by Tian and Tsou, Biochemistry 21, pp 
1028-1032, (1982). Significant, and in most cases total, 
inactivation of the enzyme will occur if the inhibitor 
concentration is chosen to be 5 to 50 times the enzyme 
concentration. The 7-amino-4-chloro-3-methox-
yisocoumarin is an essentially stoichiometric inactivator 
of PP elastase and chymotrypsin. 
The rate at which the enzyme is inactivated can be 
altered by changing both R, Z, and Y. The structures 
with long alkoxy or benzyloxy substituents are best at 
TABLE I 45 inhibiting chymotrypsin, while the most effective HL 
---------------------- elastase inhibitors contain Z groups of Cl and C14 al-
Inactivation of Proteases by 3,4-Dichloroisocoumarin°. kyloxy. Isocoumarin itself (X=O, Z= y =H, and 
Enzyme 
Human Leukocyte Elastaseh 
Porcine Pancreatic Elastase 
Human Leukocyte Cathepsin G 
Rat Mast Cell Protease I 
Rat Mast Cell Protease nh 
Human Skin Chymase 
Bovine Chymotrypsin-A 


































effective inhibitors of the blood coagulation proteases 
50 and other trypsin-like enzymes was 3,4-
dichloroisocoumarin (Z= Y =Cl, R=H, X=O). At-
tachment of positively charged groups such as guani-
dine or amines in R or Z would make the inhibitor 
reactive towards trypsin-like enzymes. Additional spec-
55 ificity towards a particular protease could be achieved 
by the placing the proper aminoacid or peptide deriva~ 
tive on the 7-amino group. Thus the specificity or gen-
erality of the inhibition reaction can be controlled first, 
by choosing the appropriate inhibitor structure and 
60 second, by choosing the inhibitor concentration uti-
lized. 
TABLE II 
Rate Constants (kobsdl[I]) for Inactivation of Serine Proteases 
by Substituted-4-chloroisocoumarins0 • 
Enz me 
Cat ad ChyF RMCP IV SGPAg 





Rate Constants (kobsdl[I)) for Inactivation of Serine Proteases 
bl:'. Substituted-4-chloroisocoumarins0 . 
Enzl:'.me 
Inhibitor HLEh PPEC Cat Gd ChyT' RMCPUf SGPAK 
isocoumarin 
3-isobutyloxy- 9500 Nii 190 750 920 6400 
4-chloroisocoumarin 
3-benzyloxy- 1525 6 1140 1600CJk 9600 5500 
4-chloroisocoumarin 
3-(4-fluorobenzyloxy- 2300 NI 216 320001 3200 3350 
4-chloroisocoumarin 
7-nitro-3-methoxy- 2580 580 
4-chloroisocoumarin 
7-nitro-3-ethoxy- 2800 1300 NI 4300 7000 2700 
4-chloroisocoumarin 
7-nitro-3-benzyloxy- 2600 10500 10500 
4-chloroisocoumarin 
7-amino-3-methoxy- 14000 1035 17 108 130 40 
4-chloroisocoumarin 
7-amino-3-ethoxy- 9420 700 195 274 876 216 
4-chloroisocoumarin 
7-(Tos-Phe-NH)- 190000 6480 195 274 NI NI 
4-chloro-3-methoxy-
isocoumarin 
"Conditions were 0.1 M Hepes, 0.5 M NaCl, pH 7.5, 10% Me2SO, at 25° C. Rate constants were 
obtained by the incubation method unless otherwise noted. An aliquot of inhibitor was added to a 
solution of enzyme and aliquots removed with time and assayed for remaining enzymatic activity. The 
first order rate constants, kobsd• were obtained from plots of In (v/v0 ) versus times. The units of 
kobsdl[I] are M- 1s- 1. 
hinhibitor concentrations were from 0.007 to 0.011 mM. 
CJnhibitor concentrations were from 0.037 to 0.011 mM. 
dlnhibitor concentrations were from 0.113 to 0.009 mM. 
t'Jnhibitor concentrations were from 0.013 to 0.098 mM. 
IInhibitor concentrations were from 0.030 to 0.009 mM. 
8J.nhibitor concentrations were from 0.086 to 0.005 mM. 
hprogress curve method with [I] = 175-600 nM. 
;Progress curve method with [I] = 0.012 mM . 
.i:NI, no inactivation 
kProgress curve method with [I] = 0.0003-0.0017 mM. 
1Progress curve method with [I] = 0.0012 mM. · 
The spontaneous hydrolysis rates of many of these 
substituted isocoumarins in buffer solution have been 40 
measured and are summarized in Table III. The hydro-
lysis rates are dependent upon the composition of the 
buffer. In general, these isocoumarins are more stable in 
phosphate buffered saline (pH 7.4) than in Hepes buffer 
(pH 7.5). The most stable inhibitor studied was 7-amino- 45 
3-methoxy-4-chloroisocoumarin while the most unsta-
ble was 3,4-dichloroisocoumarin. In addition, 7-amino-
3-methoxy-4-chloroisocoumarin is quite stable in albu-
min (0.4 mg/ml) while 3,4-dichloroisocoumarin decom-
posed rapidly upon addition to albumin (0.4 mg/ml). 50 
The 3-alkoxy-4-chloroisocoumarins are intermediate in 
stability. These compounds are significantly more stable 
than other serine protease inhibitors such as aza-pep-
tides and sulfonyl fluorides. 
TABLE III-continued 
Half-lives for Spontaneous Hydrolysis of Substituted Isocoumarins 








aspontaneous hydrolysis rates were measured spectrophotometrically by monitor· 
ing the decrease in absorbance due to the isocoumarin ring system (wavelength 
range: 385-325 nm) and these rates converted to half-lives using the first order rate 
law. 
bConditions were: 0.1 M Hepes buffer, 0.5 M NaCl, 10% Me2SO at 25° C. 
<Conditions were: 0.02 M K2HP04, 0.15 M NaCl, 10% Me2SO at 25' C. 
It has been found that certain heterocyclic com-
pounds will inhibit serine proteases such as elastase and 
chymotrypsin by blocking the active site of the enzyme. 
The compounds of this invention are 3-substituted-7-
substituted-(1H)2-benzopyran-l,4(3H)-diones. The un-
substituted (1H)2-benzopyran-l,4(3H)-dione has been 
TABLE III 55 prepared previously for other purposes (cf. Knott, J. 
Half-lives for Spontaneous Hydrolysis of Substituted Isocoumarins 



























Chem. Soc., pp 402-410 (1963). The heterocyclic serine 





R1 is selected from the group consisting of H, halo-
gen, C1-6 alkyl, C1-6 alkyl with an attached phenyl, C1-6 
fluorinated alkyl, C1-6 alkoxy, C1-6 fluorinated alkoxy, 
C1-6 alkoxy with an attached phenyl, benzyloxy, 4-
fluorobenzyloxy, -OCH2C6Hs-R' (2-substituent), 5 
-OCH2C6Hs-R' (3-substituent), -OCH2C6Hs-R' (4-sub-
stituent), -OCH2C6H4-R2' (2,3-substituents), 
-OCH2C6f4-R2' (2,4-substituents), -OCH2C6H4-R2' 
(2,5-substituents), -OCH2C6H4-R2' (2,6-substituents), 
-OCH2C6f4-R2' (3,4-substituents), and -OCH2C6li4- 10 
Ri' (3,5-substituents), 
R' is selected from the group consisting of H, halo-
gen, trifluoromethyl, N02, cyano, methyl, methoxy, 
acetyl, carboxyl, OH, and amino, 
Ri is selected from the group consisting of H, OH, 15 
NH2, N02, halogen, -NH-C(NH)-NH2, -C(NH)NH2, 
C1-6 alkoxy, C1-6 fluorinated alkoxy, C1-6 alkyl, and Ct-6 
alkylamino. 
The following novel compounds are representative 
of this invention: 20 
(1H)2-benzopyran- l ,4(3H)-dione, 
3-ethyl-(1H)2-benzopyran-l,4(3H)-dione, 
3-propyl-(1H)2-benzopyran-1,4(3H)-dione, 
3-phenyl-( 1 H)2-benzopyran-1,4(3H)-dione. 
25 
These structures inhibit serine proteases by forming 
relatively stable acyl enzymes. HL elastase (0.0004 mM) 
is totally inactivated by 3-propyl-1H-2-benzopyran-
l,4(3H)-dione (0.143 mM) while chymotrypsin (0.002 
mM) is totally inhibited by this compound at a concen- 30 
tration of0.2 mM. The unsubstituted 1H-2-benzopyran-
l,4(3H)-dione is a less effective inhibitor than the propyl 
derivative towards HL elastase and chymotrypsin. 
These compounds are more potent inhibitors of HL 
elastase and chymotrypsin than cathepsin G and PP 35 
elastase. As with the substituted isocoumarins men-
tioned earlier, the specificity of these structures towards 
a particular serine protease can be partially controlled 
by the nature of the substituent groups (R1 and Ri). 
To use the above identified inhibitors in vitro, they 40 
are dissolved in an organic solvent such as dimethylsulf-
oxide or ethanol and are added to an aqueous solution 
containing the protease which is to be inhibited such 
that the final concentration of organic solvent is 25% or 
less. The inhibitors may also be added as solids or in 45 
suspension. 
The serine protease inhibitors of this invention would 
be useful in a variety of experimental procedures where 
proteolysis is a significant problem. Inclusion of these 
inhibitors in radioimmunoassay experiments would re- 50 
suit in higher sensitivity. The use of these inhibitors in 
plasma fractionation procedures would result in higher 
yields of valuable plasma proteins and would make 
purification of the proteins easier. The inhibitors dis-
closed here could be used in cloning experiments utiliz- 55 
ing bacterial cultures, yeast and E. coli and would result 
in a more easily purified cloned product in higher yield. 
It is well known in the literature that in vitro activity 
of elastase inhibitors correlates with in vivo activity in 
animal models of emphysema. Thus the novel inhibitors 60 
described here should be useful for the treatment of 
emphysema. Elastase inhibitors have been used orally, 
by injection or by instillation in the lungs in animal 
studies (cf. Powers, Am. Rev. Respir. Dis., 127, s54-s58 
(1983) and references cited therein). The inhibitors de- 65 
scribed above can be used by any of these routes. The 
article by Powers (Am. Rev. Respir. Dis., 127, s54-s58 
(1983)) is incorporated herein by reference. 
8 
Several other diseases also involve tissue destruction 
by proteases such as elastase-like and chymotrypsin-like 
enzymes (cf. Powers, Ad. in Chem., 198, 347-367 
(1982)). This article by Powers is incorporated herein 
by reference. The other diseases include pancreatitis, 
inflammation, and adult respiratory syndrome. Al-
though correlations between in vitro activity of elastase 
and chymotrypsin inhibitors and in vivo activity in 
animal models have not yet be made for these diseases, 
it is likely that such correlations will be made shortly. 
And the novel inhibitors can then be used in any cases 
where such correlations are made. 
The following examples are given to illustrate the 
invention and are not intended to limit it in any manner. 
EXAMPLE 1 
Preparation of 3-Benzyloxy-4-Chloroisocoumarin 
Homophthalic acid (0.5 g, 2. 78 mmoles) was placed in 
benzyl alcohol (5 mL) and 2 drops of concentrated 
sulfuric acid added. The reaction mixture was heated at 
60 to 80 degrees centigrade for 45 min, poured into 50 
mL of ice-cold NaHC03 (4 %) and washed with three 
portions of ethyl acetate (50 mL). The aqueous layer 
was acidified to pH 2 with concentrated HCI and al-
lowed to stand overnight. The precipitate was filtered 
and dried to give benzyl 2-carboxyphenyl acetate (300 
mg) as a white solid: R.r=0.7 (chloroform/methanol 
(9/1)). The benzyl 2-carboxyphenyl acetate (300 mg) 
was dissolved in benzene (7 mL) and PCls (474 mg, 2.28 
mmoles) added. The reaction mixture was refluxed for 
45 min and the benzene and POCIJ removed by rotary 
evaporation. Approximately one-half of the residue was 
chromatographed on silica gel using benzene as the 
eluent to give 3-benzyloxy-4-chloroisocoumarin (125 
mg) as a pale yellow solid: mp 92 deg centigrade, 
R.r=0.63 (benzene). Anal. Calcd. for C16H1103Cl: C, 
67.02; H, 3.84. Found: C, 66.83; H, 3.86. 
EXAMPLE2 
Preparation of 3-(4-Fluorobenzyloxy) 
-4-Chloroisocoumarin 
Homophthalic acid (4.0 g) was added to a solution 
containing 4-fluorobenzyl alcohol (10 mL), benzene (10 
mL) and H1S04(3 drops) and the mixture refluxed at 80 
degrees centigrade for 2 h. The reaction mixture was 
diluted with ethyl acetate (125 mL) and washed with 
4% NaHC03 (500 mL). The aqueous layer was acidified 
to pH 3 with concentrated HCI and the solution placed 
in the refrigerator overnight. The crystals which 
formed upon cooling were filtered, dissolved in methy-
lene chloride, and dried over magnesium sulfate. The 
(4-fluorobenzyl) 2-carboxyphenyl acetate was collected 
from methylene chloride as a white solid (800 mg) and 
was used without further purification. The (4-fluoro-
benzyl) 2-carboxyphenyl acetate (0.8 g) was added 
slowly to a solution of PCls (1.16 g) in benzene (10 mL) 
and the mixture refluxed at 80 degrees centigrade for 45 
min. The benzene was removed, and the residue dis-
solved in diethyl ether, and filtered. The filtrate was 
concentrated and collected with isopropyl ether as pale 
yellow needles (500 mg): mp 127, IR (CH2Ch) 1743 
cm-1. Anal. Calcd. for C16H10CIF03: 63.07; H, 3.31. 





mixture refluxed at 80° C. for 1 h. The benzene was 
removed and the residue titurated with petroleum ether. 
The crude product was purified by silica gel chroma-
tography using benzene as the eluent to give 4-chloro-7-
5 nitro-3(2-phenethoxy)isocoumarin (0.1 g) as an orange 
solid: mp 95° -100° C. (dee), one spot on TLC, RJ=0.5; 
IR (nujol) 1752 cm311. Anal. Calcd. for C17H12ClNOs: 
Preparation of 3-Isobutyloxy-4-Chloroisocoumarin 
Homophthalic acid (4.0 g) was placed in isobutanol 
(25 mL) and 3 drops of H1S04 added. The reaction 
mixture was heated for 1 h at 100-110 degrees centi-
grade, poured into 120 mL of ethyl acetate, and washed 
with 4% NaHC03 (15 mL, X 5). The combined aqueous 
washes were acidified to pH 3 using concentrated HCl 
and the resulting precipitate collected. The precipitate 10 
was dried to give isobutyl 2-carboxyphenyl acetate as a 
white solid (1.8 g). The isobutyl 2-carboxyphenyl ace-
tate (0. 7 g) was placed in a mixture of PCls (1.23 g) and 
benzene (20 mL) and the mixture heated at reflux for 30 
min. The solvent was removed and the residue purified 15 
by silica gel chromatography using benzene as the elu-
ent to give product as pale yellow needles (338 mg); mp 
48; IR (CH2Cli) 1740 cm-I. Anal Calcd. for 
C13H13Cl03: C, 61.79; H, 5.19. Found: C, 61.64; H, 5.22. 




The 4-chloro-7-nitro-3-(2-phenethoxy )isocoumarin 
(50 mg, 0.14 mmoles) was dissolved in absolute ethanol 
(50 mL) and hydrogenated using Pd-C (50 mg) for 2 h. 
After filtering over celite, the solvent was removed and 
the residue chromatographed on silica gel using methy~ 




20 phenethoxy)isocoumarin (35 mg) as yellow plates: mp 
105°-107° C; one spot on TLC, R.J=0.45; IR(CH2Cli) 
1745 cm-1; mass spectrum m/e 315 (M+ ). Anal. Calcd. 
for C17H14ClN03: C, 64.66; H, 4.47. Found: C, 64.56; 
4-Nitro-homophthalic acid (5.0 g) was suspended in 25 
benzyl alcohol (50 mL) and H1S04(3 drops) added. The 
reaction mixture was heated at 70-80 degrees centi-
grade for 45 min, diluted into 100 mL of ethyl acetate, 
and washed with 1 L of 4% NaHC03. The aqueous 
layers were combined, acidified to pH 3 using concen- 30 
trated HCl, and extracted with 500 mL of ethyl acetate. 
The ethyl acetate layer was dried over magnesium sul-
fate and concentrated to give ca. 4 g of crude product, 
which was titurated with isopropyl ether to give 3.8 
grams of benzyl 2-carboxy-4-nitrophenyl acetate: mp. 35 
171-172. Anal. Calcd. for C16H13N06: C, 60.96; H, 4.18. 
Found : C, 60.86; H, 4.18. The benzyl 2-carboxy-4-
nitrophenyl acetate (3.0 g) was slowly added to a solu-
tion of PCls (4.35 g) in benzene (150 mL) and the reac-
tion mixture stirred overnight at 25 degrees centigrade. 40 
The benzene solution was washed with 1.2 L of water, 






N-Tosyl-phenylalanine acid chloride (77 mg, 0.3 
mmoles) and 7-amino-4-chloro-3-methoxyisocoumarin 
(50 mg, 0.2 mmoles) were suspended in a mixture of 
methylene chloride/tetrahydrofuran (1:1) and triethyl-
amine (0.037 mL, in 2 mL of methylene chloride) added 
dropwise with stirring. After stirring at 25° C. for 2 h, 
the reaction solvents were removed and the residue 
dissolved in ethyl acetate. After washing with 10% 
citric acid (3X30 mL) and 4% NaHC03 (2X30 mL), 
the ethyl acetate layer was dried over magnesium sul-
fate and concentrated. The crude product was purified 
by silica gel chromatography using a 1 % mixture of 
methanol in methylene chloride and the 7-(N-tosyl-
phenylalanylamino)-4-chloro-3-methoxyisocoumarin 
(22 mg) collected from methanol/isopropyl ether as a 
pale yellow solid: mp 222°-224° C. (dee); one spot on 
TLC, RJ=0.3; IR (nujol) 1750 cm-1; mass spectrum 
a crude yellow solid. The crude product was titurated 
with isopropyl ether to give 575 mg of a yellow solid 
which was purified further by silica gel chromatogra- 45 
phy using methylene chloride as the eluent. The pure 
product was crystallized from methylene chloride to 
give 500 mg of yellow needles: mp 153-154 dee, IR 
(CH2Cli) 1785 cm-1, 1622 cm-I. Anal Calcd. for m/e 527 (M+ 1). Anal. Calcd. for C26H23ClN206S! 
C H ClNO . C 57 94. H 3 04. N 4 22 F d· C H10: C, 58.26; H, 4.53. Found: C, 58.28; H, 4.50. 16 IO 5. ' • , , • , ' . • oun . ' 50 




4-Nitrohomophthalic acid (6.0 g, 26.5 mmoles) was 
suspended in 2-phenylethanol (20 mL ), H1S04 (3 drops) 
added, and the reaction mixture heated at 120°-130° C. 
for 3.5 h. The mixture was diluted with ethyl acetate 
(200 mL) and washed with 4% NaHC03 (2X300 mL). 60 
Thin layer chromatography indicated that the product 
was contained primarily in the ethyl acetate layer. After 
concentration of the ethyl acetate layer, the solid was 
titurated with isopropyl ether to give the 2-phenylethyl 
ester of 2-carboxy-4-nitrophenylacetic acid (2.0 g) as a 65 
tan solid and was used without further purification. The 
ester (1.3 g, 3.9 mmoles) was added slowly to a solution 
of PCls (2.05 g, 9.9 mmoles) in benzene (30 mL) and the 
Preparation of 
3-Propyl-1H-2-Benzopyran-l,4(3H)-dione. 
A solution of 3-bromo,3-(l-bromobutyl)-1(3H)-
isobenzofuranone (500 mg) in Me2SO (15 mL) was 
added dropwise to a solution of 0.1 M Hepes buffer (pH 
7.5, 50 mL) containing 0.5 M NaCl and Me2SO (35 mL). 
The mixture was stirred at 25 degrees centigrade, di-
luted with water (100 mL) and extracted with ethyl 
acetate (50 mL,X2). The extracts were combined, 
washed with water (50 mL, X 5), dried over magnesium 
sulfate, and concentrated under reduced pressure. The 
residue was chromatographed on silica gel using ben-
zene as the eluent to give the product as a white solid 
(170 mg): mp 44-45 degrees centigrade; IR (nujol), 
1730, 1700 cm-I. Anal. Calcd. for C12H1203: C, 70.57; 
H, 5.92. Found: C, 70.55; H, 5.96. 
11 
4,596,822 
Other illustrative examples are given in references 
cited below: 3-chloroisocoumarin: Davies and Poole, J. 
Chem. Soc., pp 1616-1620 (1928); 3,4-
dichloroisocoumarin: Milevskaya, Belinskaya, and 
Yagupol'skii, Zhur. Org. Khim. 9, pp 2145-2149, (1973); 5 
3-methoxy-4-chloroisocoumarin and 3-ethoxy-4-
chloroisocoumarin: Tirodkar and Usgaonkar, Ind. J. 
Chem. 7, pp 1114-1116, (1969); 7-nitro-3-methoxy-4-
chloroisocoumarin and 7-amino-3-methoxy-4- 10 
chloroisocoumarin: Choksey and Usgaonkar, Ind. J. 
Chem. 14B, pp 596-598, (1976). 
What is claimed is: 
12 
-C(NH)NH2, C1-6 alkoxy, C1-6 fluorinated alkoxy, 
C1-6 alkyl, C1-6 alkylamino, M-AA, and M-NH, 
wherein AA is selected from the group consisting of 
alanine, valine, leucine, isoleucine, praline, methio-
nine, phenylalanine, tryptophan, glycine, serine, 
threonine, cysteine, tyrosine, asparagine, gluta-
mine, aspartic acid, glutamic acid, lysine, arginine, 
histidine, beta-alanine, norleucine, norvaline, al-
pha-aminobutyric acid, epsilon-aminocaproic acid, 
citrulline, hydroxyproline, ornithine, and sarco-
sine. 
wherein M is selected from the group consisting of 
hydrogen, lower alkanoyl having 1 to 6 carbons, 
carboxylalkanoyl, hydroxyalkanoyl, amino-alkan-
oyl, benzene sulfonyl, tosyl, benzoyl, and lower 
alkyl sulfonyl having 1 to 6 carbons. 
1. A process for the inhibition of the enzymatic activ-
ity of serine proteases comprising the step of adding to 15 
a medium containing the protease that amount of inhibi-
tor effective to inhibit said activity having the following 2. A process for the inhibition of enzymatic activity 
of serine proteases comprising the step of adding to a 
medium containing the protease that amount of inhibi-








X is selected from the group consisting of 0, and S, 
30 Z is selected from the group consisting of H, halogen, 
C1-6 alkyl, C1-6 alkyl with an attached phenyl , C1-6 
fluorinated alkyl, C1-6 alkoxy, C1-6 fluorinated alk-
oxy, C1-6 alkoxy with an attached phenyl, ben-
zyloxy, 4-fluorobenzyloxy, -OCH2C6Hs-R' (2-sub- 35 
stituent), -OCH2C6Hs-R' (3-substituent), 
-OCH2C6Hs-R' (4-substituent), -OCH2C6H4-R2' 
(2,3-substituents), -OCH2C6ff4-R2' (2,4-substitu-
ents), -OCH2C6ff4-Rz' (2,5-substituents), 
-OCH2C6ff4-R2' (2,6-substituents), -OCH2C6ff4- 40 
Rz' (3,4-substituents), and -OCH2C6ff4-R2' (3,5-
substituents), 
R' is selected from the group consisting of H, halo-
gen, trifluoromethyl, N02, cyano, methyl, me-
thoxy, acetyl, carboxyl, OH, and amino, 45 
Y is selected from the group consisting of H, halogen, 
trifluoromethyl, methyl, OH, and methoxy, 
R is selected from the group consisting of H, OH, 





R1 is selected from the group consisting of H, halo-
gen, C1-6 alkyl, C1-6 alkyl with an attached phenyl, C1-6 
fluorinated alkyl, C1-6 alkoxy, C1-6 fluorinated alkoxy, 
C1-6 alkoxy with an attached phenyl, benzyloxy, 4-
fluorobenzyloxy, -OCH2C6Hs-R' (2-substituent), 
-OCH2C6Hs-R' (3-substituent), -OCH2C6Hs-R' (4-sub-
stituent), -OCH2C6H4-R2' (2,3-substituents), 
-OCH2C6H4-R2' (2,4-substituents), -OCH2C6ff4-R2' 
(2,5-substituents), -OCH2C6li4-R2' (2,6-substituents), 
-OCH2C6H4-R2' (3,4-substituents), and -OCH2C6H4-
R2' (3,5-substituents), 
R' is selected from the group consisting of H, halo-
gen, trifluoromethyl, N02, cyano, methyl, me-
thoxy, acetyl, carboxyl, OH, and amino, 
Rz is selected from the group consisting of H, OH, 
NH2, N02, halogen, -NH-C(NH)-NH2, -C(NH)NH2, 
C1-6 alkoxy, C1-6 fluorinated alkoxy, C1-6 alkyl, and C1-6 
alkylamino. 
* * * * * 
